Previous studies have indicated that the growth of HR-negative/HER2-positive breast cancer may be highly dependent on the HER2 gene [29], resulting in a high pCR rate after neoadjuvant anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.